Revenue: USD 8.84 million (up 127% from Q3 2023).
Net income: USD 1.22 million (up from a loss of USD 1.45 million in Q3 2023).
Margin: 14% (up from net loss in Q3 2023). The transition to profitability was driven by revenue growth.
EPS: USD 0.074 (up from loss of USD 0.089 in Q3 2023).
All numbers shown in the chart above are for the trailing 12 month (TTM) period.
Sales exceeded analysts' expectations by 50%. Earnings per share (EPS) also exceeded analyst expectations.
Looking ahead, revenues are expected to increase by an average of 17% per year over the next three years, compared to an 8.2% growth forecast for the U.S. medical device industry.
Performance of the American medical device industry.
The company's stock price is up 13% from a week ago.
You should learn about the 1 warning sign we've spotted with Sensus Healthcare.
Do you have feedback on this article? Interested in its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
